| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000032310 |
| Receipt No. | R000036755 |
| Official scientific title of the study | Effect of the Test Food on Anti-Glycative Actions, Skin Quality and Endothelial Function |
| Date of disclosure of the study information | 2018/04/19 |
| Last modified on | 2018/04/19 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | Effect of the Test Food on Anti-Glycative Actions, Skin Quality and Endothelial Function | |
| Title of the study (Brief title) | Effect of the Test Food on Anti-Glycative Actions, Skin Quality and Endothelial Function | |
| Region |
|
|
| Condition | ||
| Condition | N/A (healthy adults) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study aims to evaluate effect of the test food on anti-glycative actions, skin quality and endothelial function. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | [1]Skin quality evaluation (Transepidermal water loss, skin moisture content, skin viscoelasticity, image analysis by VISIA, observation for skin condition by dermatologists), anti-glycation evaluation (Skin AGEs deposition, blood pentosidine), and vascular endothelial evaluation (acceleration pulse wave, arterial pressure-volume index, arterial velocity pulse index).
(1) Week 0, Week 4, Week 8, Week 12 (image analysis of Visia will be held in Week 0 and Week 12). |
| Key secondary outcomes | *Safety
[1]Blood pressure, pulsation (Week 0, Week 4, Week 8, Week 12) [2]Weight, body fat percentage, BMI (Week 0, Week 4, Week 8, Week 12) [3]Blood test (Week 0, Week 4, Week 8, Week 12) [4]Blood biochemical test (Week 0, Week 4, Week 8, Week 12) [5]Urine analysis (Week 0, Week 4, Week 8, Week 12) [6]Doctor's questions (Week 0, Week 4, Week 8, Week 12) *Other index [1]Subject's diary (From the first day of ingestion of a test material to the last day of the test) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oral intake of the test food (1 time in a day, 12 weeks) | |
| Interventions/Control_2 | Oral intake of the placebo food (1 time in a day, 12 weeks) | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | [1]Females aged 20-59 years.
[2]Individuals who are healthy and have no chronic physical disease including skin disease. [3]Individuals who are concerning on skin sagging and dullness. [4]Individuals whose written informed consent has been obtained. [5]Individuals who can have an examination in a designated day. [6]Individuals judged appropriate for the study by the principal. |
|||
| Key exclusion criteria | [1]Individuals using medical products.
[2]Individuals who used or applied a drug for treatment of disease in the past 1 month. [3]Individuals who have a history of serious hepatopathy, kidney damage, heart disease, hematological and blood disease. [4]Individual who have digestive organ disease. [5]Individuals whose systolic blood pressure is over 160mmHg or diastolic pressure is over 100mmHg. [6]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months. [7]Individuals with serious anemia. [8]Individuals who are sensitive to test product or other foods, and medical products. [9]Individuals who are or are possibly pregnant, or are lactating. [10]Individuals who have an addiction to alcohol or a mental illness. [11]Individuals who are a smoker. [12]Individuals whose bowel habit is irregular. [13]Individuals with possible changes of life style during the test period. [14]Individuals whose skin is sensitive or who is a chronic red face. [15]Individuals with skin disease, such as atopic dermatitis. [16]Individuals with probable seasonal allergy during the test period. [17]Individuals who are sensitive to cold. [18]Individuals who are busy to their own work, housework or child care and neglect skin care. [19]Individuals who cannot avoid daylight exposure during the test period. [20]Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 3 months or will ingest those foods during the test period. [21]Individuals who have a habit to use drug claiming to improve skin condition in the past 3 months. [22]Individuals who use cosmetics having a strong moisturizing effect or improving effect for wrinkle. [23]Individuals who had been conducted an operation on the test spot in the past 6months. [24]Individuals who have a habit to use drug claiming to improve skin condition in the past 3 months. [25]Individuals judged inappropriate for the study by the principal. |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Shuji Nakata |
| Organization | Medical Corporation Bokushinkai CLINTEXE Clinic |
| Division name | Head |
| Address | 4F Atago Green Hills Mori Tower 2-5-1 Atago Minato-ku Tokyo 105-6204, JAPAN |
| TEL | +81-3-5405-1059 |
| info@tes-h.co.jp | |
| Public contact | |
| Name of contact person | Ryoma Shimizu |
| Organization | TES Holdings Co., Ltd. |
| Division name | Administrative Department of Clinical Trials |
| Address | 6F University of Tokyo Entrepreneur Plaza 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033, JAPAN |
| TEL | +81-3-6801-8480 |
| Homepage URL | |
| r.shimizu@tes-h.co.jp | |
| Sponsor | |
| Institute | TES Holdings Co., Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Nippon Shinyaku Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036755 |